Abstract
Conventional treatment of autoimmune hemolytic anemia (AIHA) comprises corticosteroids and splenectomy and/or other immunosuppressive drugs for refractory/relapsed patients. Monoclonal antibodies (MoAbs) rituximab and alemtuzumab have gained widespread acceptance in the management of B-cell malignancies. More recently, they have been used to treat a number of autoantibody-mediated diseases, such as both idiopathic and secondary AIHA, with encouraging results. Herein we report an overview of the medical literature on the use of MoAbs to treat AIHA. The therapeutic mechanism of action of rituximab in the treatment of autoimmune diseases such as rheumatoid arthritis and lupus is currently a subject of considerable investigation. We have proposed that cell-associated IgG immune complexes, generated by the binding of rituximab to CD20 on B cells, may serve as decoys that attract FcγR-expressing effector cells and downregulate effector cell pathogenic action, thus reducing inflammation and tissue destruction in these diseases. We briefly review evidence that suggests that this immune complex decoy hypothesis plays a role in the therapeutic action of rituximab in AIHA, and we propose new measurements that should allow for a more complete evaluation of the importance of this mechanism in AIHA.
Keywords: Autoimmune hemolytic anemia, monoclonal antibodies, therapy, rituximab, alemtuzumab
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?
Volume: 8 Issue: 1
Author(s): Giovanni D'Arena, Ronald P. Taylor, Nicola Cascavilla and Margaret A. Lindorfer
Affiliation:
Keywords: Autoimmune hemolytic anemia, monoclonal antibodies, therapy, rituximab, alemtuzumab
Abstract: Conventional treatment of autoimmune hemolytic anemia (AIHA) comprises corticosteroids and splenectomy and/or other immunosuppressive drugs for refractory/relapsed patients. Monoclonal antibodies (MoAbs) rituximab and alemtuzumab have gained widespread acceptance in the management of B-cell malignancies. More recently, they have been used to treat a number of autoantibody-mediated diseases, such as both idiopathic and secondary AIHA, with encouraging results. Herein we report an overview of the medical literature on the use of MoAbs to treat AIHA. The therapeutic mechanism of action of rituximab in the treatment of autoimmune diseases such as rheumatoid arthritis and lupus is currently a subject of considerable investigation. We have proposed that cell-associated IgG immune complexes, generated by the binding of rituximab to CD20 on B cells, may serve as decoys that attract FcγR-expressing effector cells and downregulate effector cell pathogenic action, thus reducing inflammation and tissue destruction in these diseases. We briefly review evidence that suggests that this immune complex decoy hypothesis plays a role in the therapeutic action of rituximab in AIHA, and we propose new measurements that should allow for a more complete evaluation of the importance of this mechanism in AIHA.
Export Options
About this article
Cite this article as:
D'Arena Giovanni, Taylor P. Ronald, Cascavilla Nicola and Lindorfer A. Margaret, Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?, Endocrine, Metabolic & Immune Disorders - Drug Targets 2008; 8 (1) . https://dx.doi.org/10.2174/187153008783928370
DOI https://dx.doi.org/10.2174/187153008783928370 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemokines in Rheumatic Diseases
Current Drug Targets The Role of MIF in Hepatic Function, Oxidative Stress, and Inflammation in Thioacetamide-induced Liver Injury in Mice: Protective Effects of Betaine
Current Medicinal Chemistry Editorial: [Pleiotropic Effects of Statins: Implications for a Wide Range of Diseases]
Current Vascular Pharmacology Biomaterials and Mesenchymal Stem Cells for Regenerative Medicine
Recent Patents on Biotechnology Phosphonamide-Based Metalloproteinase Inhibitors: A New Approach to the Development of Safer Metalloproteinase Inhibitors
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Apolipoprotein E Derived Peptides Inhibit the Pro-Inflammatory Effect of Lysophosphatidylcholine
Protein & Peptide Letters NF-κB in Anti-Inflammatory Activity of Probiotics: An Update
Current Immunology Reviews (Discontinued) Periodontitis and Redox Status: A Review
Current Pharmaceutical Design Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis
Current Drug Targets Systemic Delivery of Curcumin: 21st Century Solutions for an Ancient Conundrum
Current Drug Discovery Technologies Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?
Current Pharmaceutical Design Computational Analysis of the Interaction between Ligand-Receptor Pairs
Current Pharmaceutical Design Synovial Fluid and Serum Concentrations of Inflammatory Markers in Rheumatoid Arthritis, Psoriatic Arthritis and Osteoarthitis: A Systematic Review
Current Rheumatology Reviews Update on the Molecular Genetic Studies of Behcets Disease
Current Rheumatology Reviews Synthesis, Antioxidant and Anti-inflammatory Properties of an Apocynin- Derived Dihydrocoumarin
Medicinal Chemistry The Rationale of Targeting Neutrophils with Dapsone during Glioblastoma Treatment
Anti-Cancer Agents in Medicinal Chemistry A Review Exploring Therapeutic Worth of 1,3,4-Oxadiazole Tailored Compounds
Mini-Reviews in Medicinal Chemistry IgG4-Related Disease (IgG4+MOLPS) – Diagnostic Criteria and Diagnostic Problems
Current Immunology Reviews (Discontinued) The Emerging Role of IL-1 Inhibition in Patients Affected by Rheumatoid Arthritis and Diabetes
Reviews on Recent Clinical Trials